Q linea AB
STO:QLINEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (42.9), the stock would be worth kr125.6 (643% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.8 | kr16.9 |
0%
|
| 3-Year Average | 42.9 | kr125.6 |
+643%
|
| 5-Year Average | 56.6 | kr165.98 |
+882%
|
| Industry Average | 1.9 | kr5.5 |
-67%
|
| Country Average | 2.1 | kr6.23 |
-63%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
kr202.3m
|
/ |
Jan 2026
kr11.1m
|
= |
|
|
kr202.3m
|
/ |
Dec 2026
kr128.3m
|
= |
|
|
kr202.3m
|
/ |
Dec 2027
kr227.3m
|
= |
|
|
kr202.3m
|
/ |
Dec 2028
kr356.2m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Q linea AB
STO:QLINEA
|
320.2m SEK | 5.8 | -1.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 15.5 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 3.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 5.2 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 3.5 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 4.6 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7.1 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 10.5 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 2.7 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 5.6 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 5.1 |
| Max | 15 188 |
Other Multiples
Q linea AB
Glance View
Q-linea AB operates as a holding company. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2018-12-07. The firm develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The firm's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). The company measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. The company is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
